Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
small interfering RNA targeting TUBB2A
- Development stage
- Preclinical
- Lead developer
- JenKem Technology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
Small interfering RNA (siRNA) targeting TUBB2A is an experimental RNA interference (RNAi) therapeutic designed to silence the expression of the **Tubulin Beta 2A Class IIa (TUBB2A)** gene. TUBB2A is a member of the beta-tubulin family, which are critical structural components of microtubules involved in cell division, intracellular transport, and maintaining cell shape. Recent research has identified TUBB2A as a significant oncogenic driver and prognostic biomarker in **hepatocellular carcinoma (HCC)**, where its expression is linked to disrupted cholesterol metabolism and poor patient outcomes. The siRNA works by incorporating into the RNA-induced silencing complex (RISC), which then guides the sequence-specific cleavage and degradation of TUBB2A mRNA. This knockdown prevents the translation of the TUBB2A protein, thereby inhibiting tumor cell proliferation and potentially reversing metabolic signatures associated with hepatic oncogenesis.
- Other names
- TUBB2A siRNATUBB-2A siRNATUBB 2A siRNATUBB2A-targeting siRNATUBB-2A-targeting siRNATUBB 2A-targeting siRNA
02
Targets
TUBB2A (Tubulin beta-2A chain)
Beyond the preview
Go deeper on small interfering RNA targeting TUBB2A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on small interfering RNA targeting TUBB2A.